| Mr Salah M Neberai, MD | |
|
110 Elden St, D, Herndon, VA 20170-4891 | |
| (703) 471-6996 | |
| (703) 435-7762 |
| Full Name | Mr Salah M Neberai |
|---|---|
| Gender | Male |
| Speciality | Pediatrics - Hospice And Palliative Medicine |
| Location | 110 Elden St, Herndon, Virginia |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1497831051 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2080H0002X | Pediatrics - Hospice And Palliative Medicine | 0101058221 (Virginia) | Primary |
| Entity Name | Privia Medical Group Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1013042480 PECOS PAC ID: 4385682061 Enrollment ID: O20140603000011 |
News Archive
Children from low income environments appear to have a higher risk of neurological impairment than those from more economically secure circumstances, according to researchers at the National Institutes of Health and other institutions. This neurological impairment appears to be distinct from the risk of cognitive and emotional delays known to accompany early-life poverty.
The research team led by Prof. WEI Haiming and Prof. TIAN Zhigang from Division of Life Sciences and Medicine, University of Science and Technology of China of the Chinese Academy of Sciences, collaborating with the research group led by Prof. SUN Zimin from the First Affiliated Hospital of USTC revealed the pathological mechanism of severe pre-engraftment syndrome (PES) after umbilical cord blood transplantation, not only providing a treatment strategy for patients with PES, but significantly guiding for further improvement in the curative effect of unrelated cord blood transplantation (UCBT).
Amgen and Millennium: The Takeda Oncology Company, a subsidiary of Takeda Pharmaceutical Company Limited , today announced that enrollment in the Phase 3 MONET1 trial evaluating motesanib (AMG 706) in combination with paclitaxel and carboplatin for the first-line treatment of advanced non-small cell lung cancer (NSCLC) has been temporarily suspended following a planned safety data review of 600 patients by the study's independent Data Monitoring Committee (DMC). Motesanib is part of a broad co-development program between Amgen and Takeda.
A rapid, evidence-based review summarizes the effectiveness of cloth masks in protecting health care clinicians from respiratory viral infections, such as COVID-19. Nine studies were included in the review, and all but one were conducted prior to the COVID-19 pandemic.
Too little attention is paid to improving the delivery of clinical preventive services to adolescents by addressing problems unique to that population, says a new study commissioned by Partnership for Prevention.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mr Salah M Neberai, MD 110 Elden St, D, Herndon, VA 20170-4891 Ph: (703) 471-6996 | Mr Salah M Neberai, MD 110 Elden St, D, Herndon, VA 20170-4891 Ph: (703) 471-6996 |
News Archive
Children from low income environments appear to have a higher risk of neurological impairment than those from more economically secure circumstances, according to researchers at the National Institutes of Health and other institutions. This neurological impairment appears to be distinct from the risk of cognitive and emotional delays known to accompany early-life poverty.
The research team led by Prof. WEI Haiming and Prof. TIAN Zhigang from Division of Life Sciences and Medicine, University of Science and Technology of China of the Chinese Academy of Sciences, collaborating with the research group led by Prof. SUN Zimin from the First Affiliated Hospital of USTC revealed the pathological mechanism of severe pre-engraftment syndrome (PES) after umbilical cord blood transplantation, not only providing a treatment strategy for patients with PES, but significantly guiding for further improvement in the curative effect of unrelated cord blood transplantation (UCBT).
Amgen and Millennium: The Takeda Oncology Company, a subsidiary of Takeda Pharmaceutical Company Limited , today announced that enrollment in the Phase 3 MONET1 trial evaluating motesanib (AMG 706) in combination with paclitaxel and carboplatin for the first-line treatment of advanced non-small cell lung cancer (NSCLC) has been temporarily suspended following a planned safety data review of 600 patients by the study's independent Data Monitoring Committee (DMC). Motesanib is part of a broad co-development program between Amgen and Takeda.
A rapid, evidence-based review summarizes the effectiveness of cloth masks in protecting health care clinicians from respiratory viral infections, such as COVID-19. Nine studies were included in the review, and all but one were conducted prior to the COVID-19 pandemic.
Too little attention is paid to improving the delivery of clinical preventive services to adolescents by addressing problems unique to that population, says a new study commissioned by Partnership for Prevention.
› Verified 1 days ago
Subarna B Dharia, MD Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 12950 Highland Crossing Drive, Ste. H, Herndon, VA 20171 Phone: 703-860-4200 Fax: 703-860-1528 | |
Mrs. Jennifer P Ferrer, M.D. Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 12950 Highland Crossing Drive, Ste. H, Herndon, VA 20171 Phone: 703-860-4200 Fax: 703-860-1528 | |
Kalpana Thammineni, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 171 Elden Street, 200, Herndon, VA 20170 Phone: 305-984-6031 | |
Dr. Shadi Tabba, Pediatrics Medicare: Medicare Enrolled Practice Location: 171 Elden St, Suite 2c4, Herndon, VA 20170 Phone: 571-612-2606 | |
Deborah D Foley, M.D. Pediatrics Medicare: Medicare Enrolled Practice Location: 12930 Worldgate Dr Ste 300, Herndon, VA 20170 Phone: 703-657-5500 | |
Mr. Amin Akhlaghi, M.D. Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 12950 Highland Crossing Dr Ste H, Herndon, VA 20171 Phone: 703-860-4200 |